Blog
About

3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) show marked therapeutic efficacy in patients with non-small cell lung cancer (NSCLC) harboring the echinoderm microtubule-associated protein-like 4-ALK fusion gene. The effect on overall survival (OS) of sequential treatment with the first- and second-generation ALK-TKIs crizotinib and alectinib, respectively, has remained unknown. We have examined the clinical outcome of such sequential treatment in a retrospective analysis of patients with ALK-rearranged NSCLC.

          Related collections

          Author and article information

          Journal
          Clin Lung Cancer
          Clinical lung cancer
          Elsevier BV
          1938-0690
          1525-7304
          Nov 2016
          : 17
          : 6
          Affiliations
          [1 ] Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka, Japan.
          [2 ] Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka, Japan. Electronic address: hayashi_h@dotd.med.kindai.ac.jp.
          [3 ] Department of Medical Oncology, Kishiwada Municipal Hospital, Osaka, Japan.
          [4 ] Department of Pharmacy, Kinki University Hospital, Faculty of Medicine, Osaka, Japan.
          [5 ] Department of Medical Oncology, Izumi Municipal Hospital, Osaka, Japan.
          Article
          S1525-7304(16)30106-1
          10.1016/j.cllc.2016.05.001
          27318655

          OS, PFS, ALK-TKI, NSCLC, Anaplastic lymphoma kinase

          Comments

          Comment on this article